MAP2K7 and neuroblastoma: The finding by Umapathy et al. that ALK-activated neuroblastoma cells are resistant to the MEK inhibitor, trametinib, due to PI3K/AKT-driven feed-back response is of interest46 with regards to the known crosstalk between the MAPK and PI3K/AKT pathways.